Uherek C - Search Results

1

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells.

Müller T, Uherek C, Maki G, Chow KU, Schimpf A, Klingemann HG, Tonn T, Wels WS. Müller T, et al. Among authors: uherek c. Cancer Immunol Immunother. 2008 Mar;57(3):411-23. doi: 10.1007/s00262-007-0383-3. Epub 2007 Aug 24. Cancer Immunol Immunother. 2008. PMID: 17717662 Free PMC article.

2

Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction.

Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann HG, Wels W. Uherek C, et al. Among authors: uherek b. Blood. 2002 Aug 15;100(4):1265-73. Blood. 2002. PMID: 12149207 Free article.

3

Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors.

Wels W, Biburger M, Müller T, Dälken B, Giesübel U, Tonn T, Uherek C. Wels W, et al. Among authors: uherek c. Cancer Immunol Immunother. 2004 Mar;53(3):217-26. doi: 10.1007/s00262-003-0482-8. Epub 2003 Dec 24. Cancer Immunol Immunother. 2004. PMID: 14704833 Free PMC article. Review.

4

NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin.

Esser R, Müller T, Stefes D, Kloess S, Seidel D, Gillies SD, Aperlo-Iffland C, Huston JS, Uherek C, Schönfeld K, Tonn T, Huebener N, Lode HN, Koehl U, Wels WS. Esser R, et al. Among authors: uherek c. J Cell Mol Med. 2012 Mar;16(3):569-81. doi: 10.1111/j.1582-4934.2011.01343.x. J Cell Mol Med. 2012. PMID: 21595822 Free PMC article.

5

CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.

Romanski A, Uherek C, Bug G, Seifried E, Klingemann H, Wels WS, Ottmann OG, Tonn T. Romanski A, et al. Among authors: uherek c. J Cell Mol Med. 2016 Jul;20(7):1287-94. doi: 10.1111/jcmm.12810. Epub 2016 Mar 23. J Cell Mol Med. 2016. PMID: 27008316 Free PMC article.

6

Chimeric antigen receptors for the retargeting of cytotoxic effector cells.

Uherek C, Groner B, Wels W. Uherek C, et al. J Hematother Stem Cell Res. 2001 Aug;10(4):523-34. doi: 10.1089/15258160152509136. J Hematother Stem Cell Res. 2001. PMID: 11522235 Review.

7

DNA-carrier proteins for targeted gene delivery.

Uherek C, Wels W. Uherek C, et al. Adv Drug Deliv Rev. 2000 Nov 15;44(2-3):153-66. doi: 10.1016/s0169-409x(00)00092-2. Adv Drug Deliv Rev. 2000. PMID: 11072112 Review.

8

A chimeric fusion protein containing transforming growth factor-alpha mediates gene transfer via binding to the EGF receptor.

Fominaya J, Uherek C, Wels W. Fominaya J, et al. Among authors: uherek c. Gene Ther. 1998 Apr;5(4):521-30. doi: 10.1038/sj.gt.3300614. Gene Ther. 1998. PMID: 9614577

9

A modular DNA carrier protein based on the structure of diphtheria toxin mediates target cell-specific gene delivery.

Uherek C, Fominaya J, Wels W. Uherek C, et al. J Biol Chem. 1998 Apr 10;273(15):8835-41. doi: 10.1074/jbc.273.15.8835. J Biol Chem. 1998. PMID: 9535863 Free article.

10

Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors.

Meier R, Piert M, Piontek G, Rudelius M, Oostendorp RA, Senekowitsch-Schmidtke R, Henning TD, Wels WS, Uherek C, Rummeny EJ, Daldrup-Link HE. Meier R, et al. Among authors: uherek c. Nucl Med Biol. 2008 Jul;35(5):579-88. doi: 10.1016/j.nucmedbio.2008.02.006. Epub 2008 May 2. Nucl Med Biol. 2008. PMID: 18589302

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

17 results

Search Page